These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22957712)

  • 21. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.
    Higashihara Y; Kato J; Nagahara A; Izumi K; Konishi M; Kodani T; Serizawa N; Osada T; Watanabe S
    Int J Oncol; 2014 Mar; 44(3):662-8. PubMed ID: 24398900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
    Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
    Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
    Gavilondo JV; Hernández-Bernal F; Ayala-Ávila M; de la Torre AV; de la Torre J; Morera-Díaz Y; Bequet-Romero M; Sánchez J; Valenzuela CM; Martín Y; Selman-Housein KH; Garabito A; Lazo OC;
    Vaccine; 2014 Apr; 32(19):2241-50. PubMed ID: 24530151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
    Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
    Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
    Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
    Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
    Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
    J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
    Carmichael MG; Benavides LC; Holmes JP; Gates JD; Mittendorf EA; Ponniah S; Peoples GE
    Cancer; 2010 Jan; 116(2):292-301. PubMed ID: 19924797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.
    Ueda Y; Ogura M; Miyakoshi S; Suzuki T; Heike Y; Tagashira S; Tsuchiya S; Ohyashiki K; Miyazaki Y
    Cancer Sci; 2017 Dec; 108(12):2445-2453. PubMed ID: 28949050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
    Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
    BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.
    Lee SJ; Lee SY; Lee WS; Yoo JS; Sun JM; Lee J; Park SH; Park JO; Ahn MJ; Lim HY; Kang WK; Park YS
    Invest New Drugs; 2017 Dec; 35(6):782-790. PubMed ID: 28391576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
    Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
    Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
    Soria JC; DeBraud F; Bahleda R; Adamo B; Andre F; Dientsmann R; Delmonte A; Cereda R; Isaacson J; Litten J; Allen A; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M; Camboni MG; Tabernero J
    Ann Oncol; 2014 Nov; 25(11):2244-2251. PubMed ID: 25193991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer.
    Okuno K; Sugiura F; Inoue K; Sukegawa Y
    Anticancer Res; 2014 Jun; 34(6):3045-52. PubMed ID: 24922671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
    Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
    Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.